now browsing by category
Seattle Genetics has a sculpture that models the human antibody. Seattle Genetics centers on the study, manipulation, and packaging of antibodies into drugs since its foundation in 1998. The company’s antibodies can connect to therapies hence target cancer cells through the delivery of toxic payloads which destroy the cells from the inside. The technique raises the potential of the firm to be highly competitive in the industry.
Seattle Genetics prides itself on having an approximate market value of 10 billion dollars and employing 900 professionals. The company is the leading biotech in Washington. The institution invests in marketing and research. The company expects to increase its staff by 200 during 2017.
Seattle Genetics has Adcetris as its flagship product. Adcetris finds application in the treatment of Hodgkin lymphoma. The company expects the sales of the drug to take off if the clinical tests come out positive.
The company’s head and co-founder, Clay Siegall, said that Seattle Genetics is a multiproduct and an upcoming oncology organization. The president expressed his desire to create a massive company when he pointed out the multiple products in the company’s pipeline. He maintained that he did not desire to sell the business to larger firms as is almost the norm with many biotech companies. He said he would make the company turn into a big pharma. Clay Siegall expresses his ambitions in his commitment to shifting the company’s focus on drug development to managing all the complexities of marketing internationally. Dr. Siegall opened his Switzerland office that could allow Seattle to handle its global marketing.
Siegall’s company has a steep trajectory of growth. The company’s stock price keeps on rising alongside the sales. The company’s valuation also is increasing and reflects the firm’s investment in research and future buyout. Siegall keeps working against terrible odds and still manages to be a successful entrepreneur.
Dr. Clay Siegall is the president and CEO of the company he co-founded in 1998, Seattle Genetics. Through his leadership, the company continues to build an array of antibody-based therapies for cancer. Dr. Siegall aided the company in raising over 675 million dollars during the company’s capital-generating activities.
Dr. Siegall graduated with an undergraduate degree in Zoology from Maryland University and got awarded a Ph.D. in Genetics from the George Washington University. From 1988 till 1991, Dr. Siegall worked with the National Institutes of Health and later joined Bristol-Myers Institute to 1997. He then co-founded Seattle Genetics in 1998. Dr. Clay continues to be a proven leader in the biopharmaceutical field.
Clay Siegall, Ph.D. is the co-founder of Seattle Genetics. He started the company in 1998, and he is its president, CEO, and board chairman. Being a professional scientist with emphasis on cancer therapies, he founded Seattle Genetics on the grounds of rigorous research, scientific innovation, drug development practices, and a passion for aiding cancer patients. Under his leadership, Siegall has guided the firm to its current pioneering status in the development of ADCs and in obtaining the 2011 FDA approval of ADCETRIS. Collaboration with the Takeda Pharmaceutical has made ADCETRIS be a global brand that has been accepted in over 60 countries.
Siegall’s motivation and business strategy
Seattle Genetics is primarily focused on helping patients. Siegel claims that seeing the misery his father went through while suffering from cancer is what made him aware of how limited the tools were to oncologists, and now he wanted to improve the tools. After earning his Genetics doctorate from George Washington University, he spent some years working at Pharmaceutical Research Institute. It was during this time that he learned how to manage a company.
Siegall claims that when people are in their 20’s, they tend to think that they know everything. Upon reaching 30’s, they kind of recognize that they don’t. Siegall, now in his 40’s, appreciates that he does not know much, and he always tries to learn as more as he can grasp. He believes interacting with smart people who are experts in various fields is the best way that a person can learn much.
Siegel explains that collaborating with other innovators and industry leaders in cancer drug development is one of the important components of their business strategy. Siegall insists that their ADC collaborations have helped in extending their technological reach, hence giving them room to put resources into new approaches and ideas that will help patients.
Dr. Siegall has steered the capital-raising activities of Seattle Genetics into securing over $675 million through private and public financings. Siegall serves on Alder Biopharmaceuticals’ Board of Directors. He holds over a dozen patents and has authored over 70 publications.
Cancer is one of the diseases that have attracted a lot of activity from different professionals, who seek to deliver a solution to the menace to allow those affected to easily access treatment and quality treatment for that matter. Many companies have invested in this space to allow the development of technologies that are powerful and reliable in the treatment of cancer. Among professionals who have invested their time developing the cancer research industry, Clay Siegall has helped to bring together experts through Seattle Genetics, which has managed to unveil unique methods of treating the disease that do not affect the healthy cells of the patient.
Seattle Genetics pioneered the development of the ADC Technology, which allows patients to receive treatment without the worry of destroying healthy cells. The uniqueness of this technology comes in the sense that it allows experts to channel the waves on only those cells that are affected. Its adoption has been rising at a fast pace and several partnerships were signed to further develop the technology to offer specialized care to severely sick patients. Clay Siegall is confident in the development and growth of the technology and has also supported the adoption of ADCETRIS, which is a drug pipeline developed by Seattle Genetics to offer treatment to cancer patients.
About Clay Siegall
Clay Siegall is the founder and President of Seattle Genetics, a company that has championed cancer research for many years. He prides himself in bringing together a team of experts, who have helped Seattle Genetics to come up with technologies that are today supporting the treatment of cancer. As the Chief Executive Officer of Seattle Genetics, Clay Siegall has earned a reputation in the industry for calling for support from various agencies to advance research.
His educational background can be traced back to the Maryland University, where he pursued a degree in Zoology. He then proceeded to the Washington University for a PhD in Genetics. His effort has seen him receive several awards and recommendations to work with leading organizations. Clay Siegall is an author of over 70 publications, which have addressed clinical science and cancer research.